- Home
- ELDN vs ALEC Comparison
ELDN vs ALEC Comparison
Compare ELDN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- ALEC
- Stock Information
- Founded
- ELDN 2004
- ALEC 2013
- Country
- ELDN United States
- ALEC United States
- Employees
- ELDN N/A
- ALEC N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELDN Health Care
- ALEC Health Care
- Exchange
- ELDN Nasdaq
- ALEC Nasdaq
- Market Cap
- ELDN 239.6M
- ALEC 232.6M
- IPO Year
- ELDN N/A
- ALEC 2019
- Fundamental
- Price
- ELDN $4.34
- ALEC $1.86
- Analyst Decision
- ELDN Strong Buy
- ALEC Buy
- Analyst Count
- ELDN 1
- ALEC 6
- Target Price
- ELDN $16.00
- ALEC $11.75
- AVG Volume (30 Days)
- ELDN 553.2K
- ALEC 2.3M
- Earning Date
- ELDN 11-12-2024
- ALEC 11-06-2024
- Dividend Yield
- ELDN N/A
- ALEC N/A
- EPS Growth
- ELDN N/A
- ALEC N/A
- EPS
- ELDN N/A
- ALEC N/A
- Revenue
- ELDN N/A
- ALEC $61,508,000.00
- Revenue This Year
- ELDN N/A
- ALEC N/A
- Revenue Next Year
- ELDN N/A
- ALEC $71.71
- P/E Ratio
- ELDN N/A
- ALEC N/A
- Revenue Growth
- ELDN N/A
- ALEC N/A
- 52 Week Low
- ELDN $1.43
- ALEC $1.73
- 52 Week High
- ELDN $5.54
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- ELDN 42.46
- ALEC 22.54
- Support Level
- ELDN $4.32
- ALEC $1.74
- Resistance Level
- ELDN $4.76
- ALEC $2.50
- Average True Range (ATR)
- ELDN 0.39
- ALEC 0.16
- MACD
- ELDN -0.09
- ALEC 0.03
- Stochastic Oscillator
- ELDN 2.65
- ALEC 2.37
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.